TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Two recent deaths tied to counterfeit versions of investigational weight-loss drug retatrutide were reported to the FDA, according to a CBS News report cited by MedPage Today. Separately, Novo Nordisk plans to discontinue its liraglutide injection Saxenda in early 2027 because of declining sales; the source does not establish a connection between the deaths and that decision.
Two recent deaths tied to counterfeit versions of investigational weight-loss drug retatrutide were reported to the U.S. Food and Drug Administration, according to a CBS News report cited in MedPage Today’s October 13 roundup. The same roundup said Novo Nordisk plans to discontinue Saxenda, its liraglutide weight-loss injection, in early 2027 because of declining sales; the two developments are separate.
The available report identifies the retatrutide products as counterfeit versions and says the deaths were reported to the FDA. It does not provide the patients’ circumstances, the source or composition of the products, or evidence establishing that retatrutide itself caused either death. Retatrutide is described as an investigational medication, not an approved weight-loss treatment.
Separately, Novo Nordisk announced plans to discontinue liraglutide (Saxenda) in early 2027, attributing the decision to declining sales. The source gives no exact final sales date or information about how the company will manage availability while the discontinuation approaches. It does not say the move is related to the counterfeit-product reports.
The roundup also summarized other developments, including World Health Organization guidance against weight-loss drugs or bariatric surgery for children younger than 10, and an observational association between polyendocrine metabolic ovarian syndrome (PMOS) and dementia or Alzheimer’s disease in women. It said that association may be driven by metabolic conditions occurring alongside PMOS; it should not be read as proof that the syndrome causes dementia.
Risks of Unregulated Weight-Loss Products
The reported deaths draw attention to the potential danger of products sold as counterfeit versions of an investigational drug. Because the source does not describe what was in the products or establish a cause of death, the reports cannot determine the specific risk or show that authentic retatrutide was responsible. They do underscore why product identity and regulatory status matter to people seeking weight-loss treatments.
Saxenda’s planned discontinuation has a different practical significance: people using the medication may need information from their prescriber and the manufacturer about future supply and alternatives. The reported reason is declining sales, not a stated safety finding. Keeping that distinction clear helps readers avoid connecting unrelated drug-safety reports and commercial decisions.
investigational weight-loss drug retatrutide
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Separate Developments in Obesity Care
The October 13 item was a brief endocrinology news roundup, not a detailed investigation of the deaths or an announcement that retatrutide was being withdrawn. Its retatrutide item attributed the report to CBS News, while the Saxenda item described a plan announced by Novo Nordisk. These are distinct products and developments: retatrutide remains investigational in the supplied material, while Saxenda is an existing liraglutide product whose discontinuation is planned.
The same roundup covered a range of research and policy news. It reported that the WHO’s first obesity guidelines for children and adolescents recommend against weight-loss drugs or bariatric surgery for patients younger than 10. It also summarized a phase II trial in adults with overweight or obesity and type 2 diabetes, in which Zealand Pharma said petrelintide produced an average weight reduction of up to 9.2% at 28 weeks, compared with 2% for placebo. These items provide wider context for the changing treatment landscape but do not explain either the counterfeit reports or Novo Nordisk’s sales decision.
“Two recent deaths tied to counterfeit versions of retatrutide were reported to the FDA.”
— CBS News, as cited by MedPage Today
counterfeit retatrutide safety warning
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Unanswered Questions on Deaths and Supply
The available report does not identify the people who died, when or where the deaths occurred, or whether they had other health conditions or used additional substances. It also does not say whether FDA investigations are underway or whether testing identified ingredients in the counterfeit products. A report to the FDA is not, by itself, a finding of causation, and the source does not confirm that retatrutide caused either death.
For Saxenda, the roundup does not specify the exact date in early 2027 when discontinuation will take effect, whether availability will vary by market, or what support will be offered to current users. The PMOS summary likewise describes an association with dementia and Alzheimer’s disease, not proof of cause; the stated possible role of metabolic comorbidities remains an interpretation of the reported research.
Saxenda liraglutide weight-loss injection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Regulatory Details and Saxenda Timing
Further information from the FDA or reporting organizations would be needed to clarify the circumstances of the counterfeit-retatrutide deaths, what the products contained, and whether authorities have reached any conclusions. Until then, the supplied reporting supports only that two deaths were reported to the agency, not that a causal link has been established.
Novo Nordisk’s stated target is to discontinue Saxenda in early 2027. Patients taking the medication should seek current supply and treatment guidance from their health-care professional rather than assume a specific stop date or substitute. The source provides no further implementation timetable.
weight-loss medication alternatives
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Were the deaths confirmed to have been caused by retatrutide?
No causal finding is provided. The report says two deaths tied to counterfeit versions were reported to the FDA, but it does not establish that retatrutide caused them.
Is retatrutide an approved weight-loss drug?
The supplied report describes retatrutide as investigational. It does not describe it as an approved treatment.
Why is Novo Nordisk discontinuing Saxenda?
The company’s stated reason, as summarized by MedPage Today, is declining sales. The report does not present the decision as a response to the counterfeit-product deaths or a safety withdrawal.
When will Saxenda be discontinued?
Novo Nordisk’s plan is for discontinuation in early 2027. The source does not give an exact date or further details about availability.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
